No Data
No Data
ADR Japanese stock ranking~ highs and lows vary, Chicago is 22,500 yen higher than Osaka at 35,275 yen~
In comparison to the Tokyo Stock Exchange (converted at 1 USD = 146.68 JPY), ADRs of Japanese stocks such as Japan Post Holdings Co. Ltd. (6178), Honda Motor Co., Ltd. (7267), Renesas Electronics Corporation (6723), and Mizuho Financial Group, Inc. (8411) rose, while Yucho Bank (7182), Toyota Industries Corporation (6201), Nidec Corporation (6594), and Murata Manufacturing Co., Ltd. (6981) fell, and the overall situation was mixed. The settlement price of Chicago Nikkei 225 futures was 35,275 JPY, up 225 JPY from Osaka daytime trading, in the US stock market.
ADR Japanese stock rankings ~ Tokyo Elec and other general buy advantage, Chicago is 35,575 yen, 795 yen higher than Osaka.
Japanese stocks of American depositary receipts (ADR), converted at the rate of 1 dollar to 147.21 yen compared to the Tokyo Stock Exchange, such as Tokyo Electron <8035>, Recruit Holdings <6098>, Softbank Group <9984>, Fujitsu <6702>, Terumo <4543>, Disco <6146>, Advantest <6857>, etc., rose, and the overall trend was buying. The Chicago Nikkei 225 futures settlement price was 35,575 yen, 795 yen higher than the Osaka daytime comparison. The US stock market rebounded. The Dow Jones Industrial Average rose 683.04 dollars to 3.
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
Express News | Takeda Shares Are Trading Higher After the European Commission Approved Adzynma for ADAMTS13 Deficiency in Children and Adult Patients With Congenital Thrombotic Thrombocytopenic Purpura
Express News | The European Commission Approves Takeda's Adzynma For ADAMTS13 Deficiency In Children And Adult Patients With Congenital Thrombotic Thrombocytopenic Purpura
Veritas In Silico --- In the second quarter, drug discovery research with each partner in the mRNA-targeting small molecule drug discovery business is progressing smoothly.
Veritas In Silico <130A> announced its financial results for the second quarter of the fiscal year ending December 2024 (January to June 2024), with business revenue of 11.5 billion yen, operating loss of 6.6 billion yen, ordinary loss of 8.8 billion yen, and net loss of 9.0 billion yen. As we didn't prepare the quarterly financial statements for the interim period ended December 2023, we didn't describe the year-over-year changes for the interim period ending December 2024. In the mRNA targeted small molecule drug discovery business, we are engaged in drug discovery.